Semin Respir Crit Care Med 2006; 27(2): 171-184
DOI: 10.1055/s-2006-939520
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Parasitic Pulmonary Eosinophilia

Rajinder K. Chitkara1 , Ganesh Krishna1
  • 1Division of Pulmonary and Critical Care Medicine, Veterans Affairs Palo Alto Healthcare System, Stanford University School of Medicine, Palo Alto, California
Further Information

Publication History

Publication Date:
13 April 2006 (online)

ABSTRACT

Parasitic infections, although common in tropical and subtropical regions, are prevalent worldwide because of changing immigration patterns and in international travel. The burden of worm infection is enormous and the intensity of infection is usually high among the poor and in immunocompromised individuals. Pulmonary eosinophilia occurs in almost all metazoan infections. In the Western world, the most common infections are caused by Strongyloides, Ascaris, Toxocara, and Ancylostoma species. Most of the nematodes multiply within the human host and cause pulmonary eosinophilia during larval migration through the lungs. Despite larval migration through the lungs, there is usually no permanent lung damage. The result is an increased number of eosinophils in the airways or lung parenchyma with or without peripheral eosinophilia. Loffler's syndrome, visceral larva migrans, and tropical pulmonary eosinophilia are the most common infections that cause pulmonary eosinophilia. The most serious parasitic eosinophilic lung disease is tropical pulmonary eosinophilia, a disorder caused by the filarial worms Wuchereria bancrofti and Brugia malayi, in which cases have typically been reported to masquerade acute or refractory bronchial asthma. Increasing awareness, newer diagnostic techniques, preventative measures, and antiparasitic drugs are important in reducing the worldwide morbidity and mortality from parasitic helminths and protozoa. This review focuses on common and some uncommon causes of pulmonary parasitic eosinophilia and their manifestations, diagnosis, and management.

REFERENCES

  • 1 Rothenberg M E. Eosinophilia.  N Engl J Med. 1998;  338 1592-1600
  • 2 Gleich G J, Adolphson C R, Leiferman K M. The biology of eosinophilic leukocyte.  Annu Rev Med. 1993;  44 85-101
  • 3 Sanderson C J. Interleukin-5, eosinophils, and disease.  Blood. 1992;  79 3101-3109
  • 4 Mossman T R, Coffman R L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties.  Annu Rev Immunol. 1989;  7 145-173
  • 5 Schmid-Grendelmeier P, Altznauer F, Fischer B et al.. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.  J Immunol. 2002;  169 1021-1027
  • 6 Resnick M B, Weller P F. Mechanism of eosinophil recruitment.  Am J Respir Cell Mol Biol. 1993;  8 349-355
  • 7 Elsner J, Kapp A. The chemokines network in eosinophil activation.  Allergy Asthma Proc. 2001;  22 139-148
  • 8 Tefferi A. Blood eosinophilia: A new paradigm in disease classification, diagnosis, and treatment.  Mayo Clin Proc. 2005;  80 75-83
  • 9 Capron M. Eosinophils and parasites.  Ann Parasitol Hun Comp. 1991;  66(Suppl 1) 44-45
  • 10 Weller P F. Parasitic pneumonias. In Pennington JE (Ed). Respiratory infections: diagnosis and management (2nd ed.) New York; Raven Press 1994: 695-714
  • 11 Zumla A I, James D J. Immunologic aspects of tropical disease.  Clin Chest Med. 2002;  23 283-308
  • 12 Allen J N. Eosinophilic lung diseases.  Pul Crit Care Update. 2005;  18 1-8
  • 13 Sarinas P SA, Chitkara R K. Ascariasis and hookworm.  Semin Resp Infect. 1997;  12 130-137
  • 14 Awan A, Fein A M. Arunabh . Tropical lung diseases.  Pul Crit Care Update. 2004;  16 1-9
  • 15 Rexroth G, Keller C. Chronic course of eosinophilic pneumonia in infections with Ascaris lumbricoides. .  Pneumologie. 1995;  49 77-83
  • 16 Liu L X, Weller P F. Antiparasitic drugs.  N Engl J Med. 1996;  334 1178-1183
  • 17 Neva F A. Biology and immunology of human strongyloidiasis.  J Infect Dis. 1986;  153 397-406
  • 18 Salata R A. Intestinal nematodes. Parasitic lung diseases. In Mahmoud AAF Lung biology in health and disease. New York; Marcel Dekker 1997: 89-108
  • 19 Wehner J H, Kirsch C M. Pulmonary manifestations of strongyloidiasis.  Semin Resp Infect. 1997;  12 122-129
  • 20 Siddiqui A A, Berk S L. Diagnosis of Strongyloides stercolaris infection.  Clin Infect Dis. 2001;  33 1040-1047
  • 21 Ottesen E A, Nutman T B. Tropical pulmonary eosinophilia.  Annu Rev Med. 1992;  43 417-422
  • 22 Sakakibara A, Baba K, Niwa S et al.. Visceral larva migrans due to Ascaris summ which presented with eosinophilic pneumonia and multiple intrahepatic lesions with severe eosinophil infiltration. Outbreak in a Japanese area other than Kyushu.  Intern Med. 2002;  41 574-579
  • 23 Chitkara R K, Sarinas P SA. Dirofilaria, visceral larva migrans, and tropical pulmonary eosinophilia.  Semin Resp Infect. 1997;  12 138-148
  • 24 Ong R KC, Doyle R L. Tropical pulmonary eosinophilia.  Chest. 1998;  113 1673-1679
  • 25 Feldman G J, Parker H W. Visceral larva migrans associated with hypereosinophilic syndrome and the onset of asthma.  Ann Intern Med. 1992;  116 838-840
  • 26 Ray D, Abel R, Selvaraj K G. Epidemiology of pulmonary eosinophilia in rural South India. A prospective study, 1981-1986.  J Epidemiol Community Health. 1993;  47 469-474
  • 27 Low G L. An interesting case of eosinophilia.  Trans R Soc Trop Med Hyg. 1916;  9 77-81
  • 28 Weingarten R J. Tropical eosinophilia.  Lancet. 1943;  1 103-105
  • 29 Donohugh D L. Tropical eosinophilia. An etiologic inquiry.  N Engl J Med. 1969;  269 1357-1364
  • 30 Jeffrey H C, Leach R M, Cowan G O. Atlas of medical helminthology and protozoology (3rd Ed). New York; Churchill Livingstone 1991: 77
  • 31 Udwadia F E. Tropical eosinophilia. A review.  Respir Med. 1993;  87 17-21
  • 32 Khoo F Y, Dhanraj T J. The roentgenographic appearance of eosinophilic lung (tropical eosinophilia).  AJR Am J Roentgenol. 1960;  83 251-259
  • 33 Nath G, Mohapatra T M, Sen P C. Circulating immune complexes and complement levels in bancroftian filariasis.  Indian J Pathol Microbiol. 1991;  34 92-98
  • 34 Ray D, Sri Krishna K. Alpha1 antitrypsin in tropical pulmonary eosinophilia.  Chest. 1993;  104 487-492
  • 35 Sharma S K, Pande J N, Khilnani G C, Verma K, Kham M. Immunologic and pulmonary function abnormalities in tropical eosinophilia.  Indian J Med Res. 1995;  101 98-102
  • 36 Narayanan K, Balakrishnan A, Miyamoto S. NF-kappaB is essential for induction of proinflammatory cytokine genes by filarial parasite sheath proteins.  Mol Immunol. 2000;  37 115-123
  • 37 Lobos E, Ondo A, Ottesen E A, Nutman T B. Biochemical and immunologic characterization of a major IgE-inducing filarial antigen of Brugia malayi and implications for the pathogenesis of tropical pulmonary eosinophilia.  J Immunol. 1992;  149 3029-3034
  • 38 Ottesen E A. Efficacy of diethylcarbamazine in eradicating infection with lymphatic dwelling filariae in humans.  Rev Infect Dis. 1985;  7 341-356
  • 39 Neva F A, Ottesen E A. Tropical (filarial) eosinophilia.  N Engl J Med. 1978;  298 1129-1131
  • 40 Rom W N, Vijayan V K, Cornelius M J et al.. Persistent lower respiratory tract inflammation associated with interstitial lung disease in patients with tropical pulmonary eosinophilia following conventional treatment with diethylcarbamazine.  Am Rev Respir Dis. 1990;  142 1088-1092
  • 41 Karnad D R, Meisheri Y V. Mebendazole with levamisole in tropical pulmonary eosinophilia: an alternative in diethylcarbamazine allergy.  Trop Doct. 1992;  22 136-137
  • 42 Ottesen E A, Campbell W C. Ivermectin in human medicine.  J Antimicrob Chemother. 1994;  34 195-203
  • 43 Narayanan K, Krishnamoorthy B, Ezhilarasan R, Miyamoto S, Balkrishnan A. Targeting apoptotic signaling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage.  Cell Biol Int. 2003;  27 375-382
  • 44 Blair D, Xu Z B, Agatsuma T. Paragonimiasis and the genus Paragonimus .  Adv Parasitol. 1999;  42 113-222
  • 45 Nakamura-Uchiyama F, Mukae H, Nawa Y. Paragonimiasis: a Japanese perspective.  Clin Chest Med. 2002;  23 409-420
  • 46 Miyazaki I, Habe S. A newly recognized mode of human infection with lung flukes, Paragonimus westermani .  J Parasitol. 1976;  62 646-648
  • 47 Uchiyama F, Morimoto Y, Nawa Y. Re-emergence of paragonimiasis in Kyushu, Japan.  Southeast Asian J Trop Med Public Health. 1999;  30 686-691
  • 48 Yokogawa M, Oshima T, Suguro T. Intradermal test for paragonimiasis.  Japanese J Parasitol. 1955;  4 32-37
  • 49 Katamine D, Imai J, Iwamoto I. Immunological study on paragonimiasis.  Tropical Medicine. 1968;  10 28-38
  • 50 Tsuji M. On the immunoelectrophoresis for helminthological researches.  Japanese J Parasitol. 1974;  23 335-345
  • 51 Ikeda T, Oikawa Y, Owashi M, Nawa Y. Parasite specific IgE and IgG levels in the serum and pleural effusion of Paragonimus westermani patients.  Am J Trop Med Hyg. 1992;  47 104-107
  • 52 Waikagul J. Sero-diagnosis of paragonimiasis by enzyme-linked immunosorbent assay and immunoelectrophoresis.  Southeast Asian J Trop Med Public Health. 1989;  20 243-251
  • 53 Intapan P M, Maleewong W, Wongkham C, Morakote N, Cha W. Monoclonal antibody capture enzyme-linked immunosorbent assay for immuno-diagnosis of human paragonimiasis heterotremus.  Journal of Tropical Medicine and Parasitology. 1999;  22 41-45
  • 54 Fu S, Xiao S H, Catto B A. Clinical use of Praziquantel in China.  Parasitol Today. 1988;  4 312-325
  • 55 Calvopina M, Guderian R H, Paredes W, Chico M, Cooper P J. Treatment of human paragonimiasis with Triclabendazole: clinical tolerance and drug efficacy.  Trans R Soc Trop Med Hyg. 1998;  92 566-569
  • 56 Ripert C, Couprie B, Moyou R, Gaillard F, Appriou M, Tribouley-Duret J. Therapeutic effects of Triclabendazole in patients with paragonimiasis in Cameroon: a pilot study.  Trans R Soc Trop Med Hyg. 1992;  86 417
  • 57 Mahmoud A AF, Abdel Wahab M F. Schistosomiasis. In: Warren KS, Mahmoud AAF Tropical and geographical medicine (2nd ed.) New York; McGraw-Hill 1990: 470-471
  • 58 Freedman D O, Kozarsky P K, Weld L H. The global emerging infections sentinel network of the international society of travel medicine.  J Travel Med. 1999;  6 94-98
  • 59 Schwartz E. Pulmonary schistosomiasis.  Clin Chest Med. 2002;  23 433-443
  • 60 Hiatt R A, Sotomayor Z R, Sanches G, Zambrana M, Knight W B. Factors in the pathogenesis of acute Schistosomiasis mansoni .  J Infect Dis. 1979;  139 659-666
  • 61 Morris W, Knauer M. Cardiopulmonary manifestations of schistosomiasis.  Semin Respir Infect. 1997;  12 159-170
  • 62 Davidson B L, El-kassimi F, Uz-zaman A, Pillai D K. The “lung shift” in treated schistosomiasis: bronchoalveolar evidence of eosinophilic pneumonia.  Chest. 1986;  89 455-457
  • 63 Cetron M S, Chitsulo L, Sullivan J J et al.. Schistosomiasis in Lake Malawi.  Lancet. 1996;  348 1274-1278
  • 64 Saconato H, Atallah A. Interventions for treating Schistosomiasis mansoni (Cochrane Database Syst Rev). In: The Cochrane Library, vol. 3. Oxford; 2001
  • 65 Shuhua X, Binggui S, Chollet J, Tanner M. Tegumental alterations in juvenile S. hematobium harbored in hamsters following Artemether treatment.  Parasitol Int. 2001;  50 175-183
  • 66 Gottstein B, Reichen J. Hydatid lung disease (echinococcosis/hydatidosis).  Clin Chest Med. 2002;  23 397-408
  • 67 Liance M, Janin V, Bresson-Hadni S, Vuitton D A, Houin R, Piarroux R. Immunodiagnosis of echinococcus infections: confirmatory testing and species differentiation by a new commercial Western blot.  J Clin Microbiol. 2000;  38 3718-3721
  • 68 Poretti D, Felleisen E, Grimm F et al.. Differential immunodiagnosis between cystic hydatid disease and other cross reactive pathologies.  Am J Trop Med Hyg. 1999;  60 193-198
  • 69 Ito A, Ma L, Schantz P M et al.. Differential serodiagnosis for cystic and alveolar echinococcosis using fractions of echinococcus granulosus cyst fluid antigen (antigen B) and E. multilocularis Protoscolex (EM 18).  Am J Trop Med Hyg. 1999;  60 188-192
  • 70 Ben-Ismail R, Rouger P, Carme B, Gentilini M, Salmon C. Comparative automated assay of anti-P1 antibodies in acute hepatic distomiasis and in hydatidosis.  Vox Sang. 1980;  38 156-168
  • 71 Dar F K, Buhidma M A, Kidwai S A. Hydatid false positive serological test results in malignancy.  BMJ. 1984;  288 1197
  • 72 Ferragut G, Ljungstrom I, Nieto A. Relevance of circulating antigen detection to follow up experimental and human cystic hydatid infections.  Parasite Immunol. 1998;  20 541-549
  • 73 Stefaniak J. Fine needle aspiration biopsy in the differential diagnosis of the liver cystic echinococcosis.  Acta Trop. 1997;  67 107-111
  • 74 Safioleas M, Miseakos E P, Dosios T, Manti C, Lambrou P, Skalkeas G. Surgical treatment of for lung hydatid disease.  World J Surg. 1999;  23 1181-1185
  • 75 Keshmiri M, Baharvahdat H, Fattahi S H et al.. A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis.  Eur Respir J. 1999;  14 503-507
  • 76 Cangiotti L, Giulini S M, Muiesan P, Begni A, Tiberio G. Hydatid disease of the liver: Long term results of surgical treatment.  G. Chir (Paris). 1991;  12 501-504
  • 77 Novick R J, Tchervenkov C I, Wilson J A, Munro D D, Mulder D S. Surgery for thoracic hydatid disease: A North American experience.  Ann Thorac Surg. 1987;  43 681-686
  • 78 Frider B, Larrieu E, Odriozola M. Long term outcome of asymptomatic liver hydatidosis.  J Hepatol. 1999;  30 228-231
  • 79 Cobo F, Yarnoz C, Sesma B et al.. Albendazole plus Praziquantel versus albendazole alone as a pre-operative treatment in intra abdominal hydatidosis caused by Echinococcus granulosus .  Trop Med Int Health. 1998;  3 462-466
  • 80 Lyche K D, Jensen W A. Pleuro-pulmonary amebiasis.  Semin Respir Infect. 1997;  12 106-112

Rajinder K ChitkaraM.B. M.D. 

Division of Pulmonary and Critical Care Medicine (111P)

3801, Miranda Ave., Bldg. 100, F2-142, Palo Alto, CA 94304

Email: rkc@stanford.edu

    >